09-18-2017 | PCSK9 inhibitors | EASD 2017 | News
A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.
09-14-2017 | PCSK9 inhibitors | EASD 2017 | News
The effect of the PCSK9 inhibitor alirocumab on dyslipidemia in patients with type 1 diabetes is consistent with that seen in the type 2 population, the ODYSSEY team has revealed.
10-26-2018 | PCSK9 inhibitors | Review | Article
Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5
06-25-2018 | Cardiovascular disorders | Review | Article
Strawbridge RJ, van Zuydam NR. Curr Diab Rep 2018; 18: 59. doi: 10.1007/s11892-018-1021-5
09-16-2016 | Dyslipidemia | Review | Article
Nat Rev Endocrinol 2017; 13: 36–49. doi: 10.1038/nrendo.2016.135